Companies › Rapa Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Neurology, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RAPA-501 Autologous T stem cells Autologous hybrid TREG/Th2 cells | – | Phase 2 | Amyotrophic Lateral Sclerosis | Jul 2027 |
| RAPA-201 Rapamycin Resistant T Cells Autologous rapamycin-resistant CD4+ and CD8+ T cells (Th1/Tc1 phenotype) with checkpoint-d | – | Phase 1 | Solid Tumor | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05144698 | RAPA-201 Rapamycin Resistant T Cells | Phase 1 | Solid Tumor | Oncology | Dec 2026 |
| NCT04220190 | RAPA-501 Autologous T stem cells | Phase 2 | Amyotrophic Lateral Sclerosis | Neurology | Jul 2027 |
No annotated target.
–
MeiraGTx Scancell Allotera Therapeutics Ever Supreme Bio Technology Diakonos Oncology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.